April 23 Coral Gables- based Catalyst Pharmaceutical Partners soon will make its investigational drug Firdapse available at no cost to patients with a certain autoimmune disorder. Catalyst said it expects to submit an application for Firdapse's approval with the U.S. Food and Drug Administration next year. Catalyst has been leading the developmen
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors LIN, Wen Jen; Alai, Milind, filed on September 28, 2012, was made available online on April 10, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to National Taiwan University.
By a News Reporter-Staff News Editor at Biotech Week Respiratory experts Phil Lake, Ph.D., of Theorem Clinical Research and Jim Sowash from ERT will present a live, interactive webinar titled "Optimal management of lung function data to drive successful respiratory clinical trial outcomes" at 10 a.m. EDT on Wednesday, April 23. "Variability in l
AbbVie today announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented at the upcoming 50 th Annual Meeting of the American Society of Clinical Oncology, May 30- June 3, in Chicago. "Our clinical trial program underscores our commitment to developing innovative therapies that improve
As a result of this transaction, Ablynx now has 49,083,327 shares outstanding. About Ablynx Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncolog
Ablynx today announced that it has started dose administration in healthy volunteers in a Phase I clinical trial as part of the evaluation of a subcutaneous formulation of its anti-IL-6R Nanobody , ALX-0061, for the treatment of inflammatory diseases, including rheumatoid arthritis and systemic lupus erythematosus. In September 2013, Ablynx and
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene Corporation, presented interim data demonstrating dose dependent increases in hemoglobin in patients with...
By a News Reporter-Staff News Editor at Biotech Week ACCESS PHARMACEUTICALS, INC. provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard?, for the treatment of inflammatory and ulcerative conditions of the esophagus. Amlexanox is a novel anti-inflammatory and anti-allergic agent that has been approved a
Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced a poster presentation at the American Academy of Neurology 66 th Annual Meeting, April 26 to May 3, 2014, in Philadelphia, PA.. The poster presentation will take place during Poster Session IV on Wednesday, April 30, 2014, from 7:30 to 11:00 a.m. The EASED study inves
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it closed a $22 M financing round led by new investor OrbiMed, with existing investors Novartis Venture Funds, Satter Investment Management, Kearny Venture Partners, Venture Investors, Triathlon
Akorn, Inc., a niche pharmaceutical company, announced that it has completed its previously announced acquisition of Hi-Tech Pharmacal Co., Inc. for $640 million in cash. According to a release, the combination of Akorn and Hi-Tech will transform the Company into a larger, more diversified generic player. This combination also brings critical mass
Alder Biopharmaceuticals Inc. today announced that Dr. Peter J. Goadsby, M.D., Ph.D., director, NIHR-Wellcome Trust Clinical Research Facility, King's College London and director, Headache Center, Department of Neurology, University of California, San Francisco, will present results from a randomized, double-blind, placebo-controlled proof-of-conce
NEW YORK, April 23, 2014/ PRNewswire-USNewswire/ The Alzheimer's Drug Discovery Foundation announced today the launch of Cognitive Vitality, a new online resource developed to provide a comprehensive and credible overview and analysis of the science for specific strategies to prevent Alzheimer's and related dementias. "Although there has been...
That's why Eli Lilly and Co. is plunking down big bucks to bulk up its animal health business as its overall sales have begun to flatten, mostly because of patent expirations on blockbuster drugs. "The growth is being fueled by the demand for protein in emerging markets and increased spending on pets in the U.S. and Europe," said Linda Bannister,
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arca Biopharma, Inc. was posted on April 4, 2014. The SEC file number is 0001193125-14-131643.. A U.S. Securities and Exchange Commission filing is a formal
Following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain assets, Array BioPharma Inc. reports that Novartis has indicated that it will continue to honor its obligations under the Array-Novartis agreement relating to binimetinib, including obligations relating to...
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on April 3, 2014. The SEC file number is 0001127602-14-014048.. A U.S. Securities and Exchange Commission filing is a formal
By a News Reporter-Staff News Editor at Biotech Week Assembly Pharmaceuticals and BioCrossroads announced that the BioCrossroads Indiana Seed Fund II has made an investment in Assembly Pharmaceuticals. Assembly Pharmaceuticals is applying its novel science to develop agents with the potential to cure chronic HBV. Assembly Pharmaceuticals was form
Avedro Inc., a Boston- based ophthalmic medical device and pharmaceutical company announces today the Canadian approval for the company s KXL II System. David Muller, PhD, CEO of Avedro states, With this approval of the KXL II, Canada joins the 28 members of the European Union that have received the CE mark and approval to use this advanced t
Baxter International Inc. today announced that the U.S. Food and Drug Administration has approved a new reconstitution system for ADVATE. ''ADVATE has the widest range of dosage formulations, allowing for more precise customized dosing, and with the ADVATE with BAXJECT III reconstitution system, patients can prepare their treatment with fewer steps
Bringing with her over 20 years of industry experience and a career spanning R %7 ED, clinical operations, and manufacturing in several multi-national pharmaceutical organizations such as Eli Lilly and Johnson %7 E Johnson, as well as smaller biotech companies and CROs, Dr. She has extensive experience ensuring strict GLP compliance for bioanalytic
BioAlliance Pharma, a Company specialized in the development of drugs in orphan oncology diseases, said that the European Independent Board of Experts, in charge of the safety profile of the ReLive Phase III trial, held its fourth meeting and once more unanimously recommended continuing the study without modification. The trial is still expanding i
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's...
By a News Reporter-Staff News Editor at Biotech Week Calgary Scientific Inc., a company known for creating transformative technology for the medical industry and beyond, announced their latest Class II clearance from the United States Food and Drug Administration. Calgary Scientific worked closely with a number of Radiologists at a world renowned
This report contains forward looking statements within the meaning of Section 27 A of the Securities Act of 1933, as amended, and Section 21 E of the Securities Exchange Act of 1934, as amended. The Company's actual results could differ materially from those set forth on the forward looking statements as a result of the risks set forth in the Compa